对补偿性环素D2反应的能力使得Trametinib在犬类粘膜黑色素瘤中具有抗性

Bih-Rong Wei1,2, Vincenzo Verdi1, Shuling Zhang1

  • 1Laboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.

Cancers
|July 29, 2025
PubMed
概括

粘膜黑色素瘤 (MM) 细胞通过从cyclin D1切换到cyclin D2.2,对Trametinib等MEK抑制剂产生抗性. 抑制性环林D2促进了生存和繁殖,导致治疗耐药性.